Apyx Medical Corp Reconstitutes Board Committee Membership

What Happened
Apyx Medical Corporation (APYX) announced on July 24, 2026 that its Board of Directors reconstituted the membership and chairs of its standing committees. The new committee lineups are: Audit Committee — Lawrence J. Waldman (Chair), Minnie Baylor-Henry, Wendy Levine; Governance & Nominating Committee — Minnie Baylor-Henry (Chair), Lawrence J. Waldman, Wendy Levine; Regulatory Compliance Committee — Minnie Baylor-Henry (Chair), Lawrence J. Waldman, Wendy Levine; Compensation Committee — Wendy Levine (Chair), Lawrence J. Waldman, Minnie Baylor-Henry. In connection with his June 11, 2026 appointment as Executive Chairman, Stavros Vizirgianakis will not serve on any Board committee.

Key Details

• Date filed: July 24, 2026 (8-K Item 8.01).
• Committee chairs and members: Lawrence J. Waldman (Audit Chair); Minnie Baylor-Henry (Governance & Regulatory Compliance Chair); Wendy Levine (Compensation Chair).
• Independence: The Board determined Mr. Waldman, Ms. Baylor-Henry and Ms. Levine are independent under Nasdaq Global Select Market and SEC rules.
• Audit expertise: The Board determined Lawrence J. Waldman qualifies as an "audit committee financial expert" under SEC rules.

Why It Matters
Changes to committee composition affect corporate oversight of key areas — audit, compliance, governance and executive compensation. The Board’s independence determinations and naming of an SEC-designated audit committee financial expert signal governance alignment with Nasdaq and SEC standards, which investors generally view as important for financial reporting integrity and accountability.